GNAQ targeted dsRNA compositions and methods for inhibiting expression

Details for Australian Patent Application No. 2009324534 (hide)

Owner Alnylam Pharmaceuticals, Inc.

Inventors Gollob, Jared; Hinkle, Gregory; Toudjarska, Ivanka; Bumcrot, David

Agent FB Rice

Pub. Number AU-A-2009324534

PCT Pub. Number WO2010/068816

Priority 61/185,543 09.06.09 US; 61/244,780 22.09.09 US; 61/121,253 10.12.08 US

Filing date 10 December 2009

Wipo publication date 17 June 2010

International Classifications

A61P 35/00 (2006.01) Antineoplastic agents

C12N 15/113 (2010.01) Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Event Publications

14 July 2011 PCT application entered the National Phase

  PCT publication WO2010/068816 Priority application(s): WO2010/068816

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009324536-Evaluation of gastrointestinal function using portable electroviscerography systems and methods of using the same

2009324521-Construction project prequalification